Pure Global AI
NCT05449847Completed

Plasma MicroRNA for Prediction of Hepatocellular Carcinoma

Plasma Expression Levels of MicroRNA-21 Might Help for Detection of HCV Patients Complicated by Hepatocellular Carcinoma
Benha UniversityClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Hepatitis C
Drug/Device/Intervention
Blood Sampling
Study type
Observational
Intervention type
biological
Sponsor & location
Primary sponsor
Benha University
Location
Banhā, Egypt
Timeline & enrollment
Phase
N/A
Start date
May 13, 2021
End date
Mar 20, 2022
Enrollment
100 participants
Primary outcome

Relation between MicroRNA and HCV

Summary

100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and
 were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78). All patients were
 evaluated for hepatosteatosis and liver fibrosis using the computerized hepatorenal index,
 the hepatic steatosis index, aspartate aminotransferase (AST)/platelet count index (APRI) and
 the Fibrosis-4 (FIB-4) scores. Blood samples were obtained for estimation of serum levels of
 liver function tests and plasma levels of microRNA 21 and 126.

ICD-10 classifications
Acute hepatitis CChronic viral hepatitis CViral hepatitisChronic viral hepatitisUnspecified viral hepatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05449847
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05449847 through Pure Global AI's free database. This phase not specified trial is sponsored by Benha University and is currently Completed. The study focuses on Hepatitis C. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.